Loading...
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Staib, Caroline Schätzl, Hermann M Ebensen, Thomas Erfle, Volker Guzman, Carlos A
Staib, Caroline
Schätzl, Hermann M
Ebensen, Thomas
Erfle, Volker
Guzman, Carlos A
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2008-12-02
Submitted date
Files
Loading...
original manuscript
Adobe PDF, 206.95 KB
Other Titles
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
Citation
A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. 2008, 26 (51):6678-84 Vaccine
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
0264-410X